Consider Whether Flozin Benefits Outweigh Risks
You'll hear more controversy about when to use SGLT2 inhibitors (Jardiance, etc) for type 2 diabetes...as more data on CV impact emerge.
Invokana (canagliflozin) joins Jardiance (empagliflozin) as a flozin that lowers CV risk when added to metformin in type 2s at high CV risk.
But Jardiance seems to have an edge. It prevents CV death in one in 45 type 2s with heart disease over 3 years...reduces overall mortality in one in 39...and slows progression of nephropathy in about one in 16.